Heart Failure & Cardiac Repair: cell-therapy evidence by therapy class
Across every stem-cell intervention, ClinicalTrials.gov holds 125 registered records for Heart Failure & Cardiac Repair — 10 recruiting, 18 at Phase 3 or 4, in 32 countries. Snapshot 2026-08-29.
The condition, and why cells are proposed
Heart failure with reduced ejection fraction involves lost cardiomyocytes and adverse remodelling. Cell therapy has been studied here longer than in almost any other indication, and the arc is instructive: early enthusiasm, mixed later-phase results, and a field that has narrowed its claims from regeneration to modest functional support.
Therapy classes side by side
Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.
Geography of the research
United States accounts for about 38% of country mentions among sampled studies; 32 countries host at least one site.
| Country | Studies with a site there |
|---|---|
| United States | 36 |
| China | 12 |
| Denmark | 8 |
| Slovenia | 7 |
| Canada | 6 |
| Germany | 6 |
| Netherlands | 5 |
| Italy | 5 |
The largest registered studies
Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT03899298 — Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions | Phase 1 | Not Yet Recruiting | 5,000 | R3 Stem Cell | 2019-09-01 |
| NCT02032004 — Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure | Phase 3 | Completed | 565 | Mesoblast, Inc. | 2014-03-03 |
| NCT05043610 — MSCs for Prevention of MI-induced HF | Phase 3 | Completed | 420 | Shiraz University of Medical Sciences | 2021-09-15 |
| NCT01569178 — BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction | Phase 3 | Completed | 375 | Queen Mary University of London | 2013-09 |
| NCT00841958 — Endocardial Stem Cells Approach Efficacy | Phase 3 | Completed | 250 | Meshalkin Research Institute of Pathology of Circulation | 2007-02 |
| NCT02323620 — Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI | Phase 3 | Unknown | 200 | American Heart of Poland | 2019-03 |
Most recently registered
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07471698 — hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease | n/a | Not Yet Recruiting | n/a | HELP Therapeutics Co., Ltd. | 2026-10-20 |
| NCT07646210 — HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery | n/a | Not Yet Recruiting | n/a | HELP Therapeutics Co., Ltd. | 2026-09 |
| NCT07496372 — A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failur | n/a | Recruiting | n/a | HELP Therapeutics Co., Ltd. | 2026-04-30 |
| NCT07192211 — Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG | n/a | Recruiting | n/a | Rohto Pharmaceutical Co., Ltd. | 2026-04-28 |
| NCT06840275 — ASCs in Recently Diagnosed Non-ischemic Heart Failure | n/a | Withdrawn | n/a | Cell to Cure ApS | 2026-03-01 |
Reading this honestly
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found. For Heart Failure & Cardiac Repair specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.
Frequently asked
How many stem-cell trials exist for Heart Failure & Cardiac Repair?
125 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 10 were recruiting.
Which therapy class is furthest along for Heart Failure & Cardiac Repair?
Ranked by Phase 3/4 records: MSC (5), HSCT (1), exosomes (0), PRP (0).
Does a recruiting trial mean I can be treated?
No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Heart Failure & Cardiac Repair: cell-therapy evidence and registered trials
- How much does stem cell therapy for Heart Failure & Cardiac Repair cost? (2026)
- Heart Failure & Cardiac Repair stem cell therapy — your questions answered (2026)
- MSC vs HSCT for Heart Failure & Cardiac Repair: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.